Showing results (1-10 of 119) with videos related to
Sort By:
Pageof 12
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2017
Emerging Strategies in Treating Double Hit LymphomasChadi Nabhan, Anthony R MatoClinical Advances in Hematology & Oncology : H&O|April 12, 2017
BCL-2 as a therapeutic target in chronic lymphocytic leukemiaCatherine Daniel, Anthony R MatoPET Clinics|May 10, 2016
Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with LymphomaAnthony R Mato, Andre GoyCancer Journal (Sudbury, Mass.)|November 26, 2019
Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted TherapiesPrioty Islam, Anthony R MatoCurrent Hematologic Malignancy Reports|May 9, 2020
Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and OpportunitiesPrioty Islam, Anthony R MatoCancer Management and Research|April 8, 2020
Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging DataKrista Isaac, Anthony R MatoPET Clinics|May 16, 2019
PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter TransformationJoanna M Rhodes, Anthony R MatoHematology/Oncology Clinics of North America|June 27, 2021
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase InhibitorsMeghan C Thompson, Anthony R MatoBlood Advances|February 11, 2021
Overcoming resistance to targeted therapies in chronic lymphocytic leukemiaSigrid S Skånland, Anthony R MatoDrug Design, Development and Therapy|March 10, 2021
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic LeukemiaJoanna M Rhodes, Anthony R MatoPageof 12